SIPO rejects Sovaldi patent as Chinese regulators turn attention to drug prices

China's State Intellectual Property Office (SIPO) last week rejected a patent application related to the hepatitis C drug Sovaldi, which is produced by Gilead Sciences. The US company already owns a Chinese patent on the drug’s main ingredient…

Get unlimited access to all IAM content